- Disease: Acute SARS-CoV-2
- Study type: Observational Cohort Study
- Study type descriptors: Retrospective, Single centre
- Study aim: To investigate whether the administration of early treatments, not only mitigates the severity of COVID-19, but substantially reduces the duration of COVID-19 test positivity
- Number of participants enrolled: 518
- Study enrolling from to
- Study includes follow-up for 2 months
- Standardisation: 0
Study Data
- Adults
- Elderly
- Fragile population
- Hospital wide
- Outpatient clinic
- SARS-CoV-2
- Acute SARS-CoV-2
- Pharmacological intervention
- Antivirals
- Remdesivir
- Monoclonal antibodies
- Nirmatrelvir/Ritonavir
- Sotrovimab
- Molnupiravir
- Tixagevimab/Cilgavimab
- Casirivimab/Imdevimab
- Bamlanivimab/ Etesevimab
External Links
Other information
Funders:
- END-VOC (GA 101046314) – Horizon Europe
If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it
The data is updated up to